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Abstract
The chronic Philadelphia-negative myeloproliferative neoplasms (MPNs) are acquired stem
cell neoplasms which ultimately may transform to acute myelogenous leukemia. Most
recently, chronic inflammation has been described as an important factor for the develop-
ment and progression of MPNs in the biological continuum from early cancer stage to the
advanced myelofibrosis stage, the MPNs being described as “A Human Inflammation Model
for Cancer Development“. This novel concept has been built upon clinical, experimental,
genomic, immunological and not least epidemiological studies. Only a few studies have
described the development of MPNs by mathematical models, and none have addressed
the role of inflammation for clonal evolution and disease progression. Herein, we aim at
using mathematical modelling to substantiate the concept of chronic inflammation as an
important trigger and driver of MPNs.The basics of the model describe the proliferation from
stem cells to mature cells including mutations of healthy stem cells to become malignant
stem cells. We include a simple inflammatory coupling coping with cell death and affecting
the basic model beneath. First, we describe the system without feedbacks or regulatory
interactions. Next, we introduce inflammatory feedback into the system. Finally, we include
other feedbacks and regulatory interactions forming the inflammatory-MPN model.
Using mathematical modeling, we add further proof to the concept that chronic inflamma-
tion may be both a trigger of clonal evolution and an important driving force for MPN disease
progression. Our findings support intervention at the earliest stage of cancer development
to target the malignant clone and dampen concomitant inflammation.
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Introduction
The classic chronic Philadelphia-negative myeloproliferative neoplasms (MPNs) include
essential thrombocythemia (ET), polycythemia vera (PV) and primary myelofibrosis (PMF),
which are acquired stem cell neoplasms [1]. Most patients live with their MPNs for decades
although with a huge morbidity burden due to a high risk of thrombosis with cardiovascular
complications and a massive comorbidity burden as well due to an increased propensity to
develop autoimmune and chronic inflammatory diseases [2–4], including a 40% increased risk
of second cancers [5,6]–not only after the MPN-diagnosis but also prior to the MPN-diagnosis
[7]. Several years prior to the MPN-diagnosis these patients also have an increased risk of car-
diovascular, autoimmune and inflammatory diseases [8,9]. Furthermore, the MPNs have an
inherent risk of transformation to acute myelogenous leukemia (AML) and myelodysplastic
syndrome (MDS) [10].
During the last decade major breakthroughs have occurred in the understanding of the
pathogenesis of the MPNs, the most important being the identification of the somatic
clonal markers–JAK2, MPL and CALR [11–18]. The findings of several other mutations
already at the time of MPN-diagnosis, with the emergence of additional mutations in the
advanced transforming stages of MPNs [17,18], all support the concept of a biological con-
tinuum from the early cancer stages (ET/PV) to the advanced cancer stages (myelofibrosis
or AML) [1,19,20]. Chronic inflammation is the common link between common diseases
such as atherosclerosis, the metabolic syndrome, type II diabetes mellitus and cancer, in
which the JAK-STAT- signalling and the NF-kB pathways are activated and have major
roles in disease progression [21–28]. These pathways are activated in MPNs as well. Most
recently, the MPNs have been described as “Inflammatory Diseases “[4] and “A Human
Inflammation Model For Cancer Development”[29] reflecting chronic inflammation to
be a major driving force for clonal evolution and disease progression in MPNs [30–39].
This novel concept is built upon a platform, which has combined data from studies in sev-
eral research fields and disciplines within MPNs—clinical [3–9,29–53], experimental [54–
63], genomic [64–70], immunological [71–74] and not least epidemiological studies [3,5–
7,75–77].
Another research field—mathematical modelling of cancer development—has not been
applied to a similar extent within MPNs until very recently [78,79] and not in the context of
investigating the concept of MPNs as “A Human Inflammation Model for Cancer Develop-
ment”. Mathematical modelling of cancer development has provided new insights regarding
cancer initiation and progression [80–89]. In this context, mathematical modelling has a
huge potential to support or disprove understanding of research data on pathogenetic fac-
tors of significance for cancer development but also in regard to providing supportive evi-
dence for a drug to be used in cancer therapy and accordingly a novel tool in evidence-
based medicine [90–92]. Mathematical modelling of chronic inflammation as the trigger
and driver of MPNs has never been investigated. Although the concept of MPNs as “inflam-
matory diseases” is being increasingly recognized, additional proof of this novel concept by
mathematical modelling might be of utmost importance not only for our understanding of
the pathogenesis of these neoplasms, but also in regard to diagnosis and treatment. Herein,
we for the first time by mathematical modelling add further proof of the concept that MPNs
may be both triggered and driven by chronic inflammation. We discuss the perspectives of
our findings, which might implicate intervention at the earliest stage of cancer development
(ET, PV) to target the malignant clone and dampen concomitant inflammation when the
tumor burden is minimal, and accordingly, the outcome of treatment is logically most
favorable.
Mathematical modeling in myeloproliferative cancer
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Methods
The system describes the proliferation from stem cells to mature cells including mutations of
healthy stem cells to become malignant stem cells. We include regulatory interactions (e.g.
niche growth effects) and inflammation coping with cell death, inflammatory cytokines, and
neutrophils. In order to design an inflammatory MPN model, we build on the coupled dynam-
ics of inflammation and cancer progression as depicted in Fig 1.
The model
Most previous studies attempting to model the role of inflammation and immune deregulation
in cancer progression consider solid tumors and couple the T-cell and natural killer (NK) cell
dynamics to a logistic growth of a tumor. They mainly describe quite simplified versions of the
adaptive immune response without explicitly considering the underlying cancer growth
dynamics [93–98]. In contrast to all these models, our model is the first which couples the
principles underlying actual cell dynamics to a basal inflammatory response. This response is
seen for a normal infection, where the amount of dead cells provokes the immune response
and stimulates the renewal of stem cells. Despite this complex coupling, the model is kept as
simple as possible still allowing the relevant quantities to be described. Thus, the goal is to
describe an important coupling between MPN development and the inflammatory response at
Fig 1. The conceptual model. Light gray boxes (symbolized x0, x1, y0, and y1) illustrate the compartments of
the basic model, and the black arrows the rates of the flows between these compartments. Here x0 denotes
the number of HSC, x1 that of HMS, y0 that of MPN SC, and y1 the number of MPN MC. The light blue
compartment (symbolized a) contains all dead cells and the light orange compartment (symbolized s) the
inflammatory level, i.e. the immune response. Blue arrows from these represent related rates of flows. Red
stipulated arrows going from the inflammatory compartment represent effects of the cytokines (or neutrophils
when eliminating dead cells) modulating rates of the basic model. Two additional rates (depending on x0 and
y0) appearing as red stipulated arrows represent the bone marrow niches symbiosis with the stem cells
modulating the self-renewal rates. Note, stem cells leaving their respective compartments enter the
corresponding mature cell-pools as multiplied by the progenitor amplification factor (A).
https://doi.org/10.1371/journal.pone.0183620.g001
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a quantitatively conceptual level. Hence, the complicated mathematical question of model
identifiability and accurate parameter estimation will be addressed elsewhere. Nevertheless, we
include some model calibration and validation after presenting the model to justify and dem-
onstrate the strength of the model.
Basically, our model consists of four pools of cells; the hematopoietic stem cells (HSC), the
hematopoietic mature cells (HMC), the MPN-mutated stem cells (MPN SC) and the MPN
mature cells (MPN MC). The number of these cells are denoted x0, x1, y0, and y1 respectively,
where x refers to normal hematopoietic cells and y to MPN hematopoietic cells, while index 0
refers to stem cells and index 1 to mature cells. A single stem cell (SC) may proliferate in three
ways; symmetric self-renewal (having two stem cells as offspring), asymmetric self-renewal
(turning into one stem cell and one progenitor cell), and symmetric differentiation (giving rise
to two progenitor cells). The progenitor cells cannot be ignored, however, we consider the pro-
genitor cells simply as intermedia multiplication steps describing the way stem cells generate
mature cells. In the model, the generations or continuum of progenitor cells will be implicitly
accounted for as each stem cell will generate a number of mature cells by an amplification fac-
tor, A (= 2k if there are k generations of progenitor cells). Feedbacks from or to progenitor cells
are ignored or integrated into the other included feedbacks.
The present focus is on the ensemble of each cell type and not the individual cells; thus the
governing laws will be for the pools of cells, in science denoted compartments [99]. Mathemat-
ically, the dynamics will be described by non-linear ordinary differential equations respecting
conservation laws. The HSC self-renews with rate rx and the malignant MPN SC self-renews
with rate ry. Furthermore, HSC may be transformed by cell division by a rate ax whereas the
MPN SC does so with a rate ay. The mature cells are multiply generated, i.e. the HMC are gen-
erated with a rate axAx and the MPN MC with a rate ayAy. Finally, all cell types may die; stem
cells with a lower rate and mature cells with a higher rate. The turnover (or mortality) rates are
dx0, dx1, dy0, and dy1 for the HSC, HMC, MPN SC, and MPN MC, respectively. Except for the
mutation part and the multiplication factor, this duplicates the structure of the model pro-
posed by Dingli and Michor (they silently used A = 1) [92].
A small probability rm describes the mutation of HSC into MPN SC. In that case, rm is not
the probability of a single mutation but possibly a serial sequence of mutations turning the
HSC into a cancer cell capable of self-renewal, by definition an MPN SC, where a mutation is
expected to be described by a Poisson process [100]. The probability for one mutation is about
10−7 per year per cell [101]. However, not all mutations are malignant; only mutations which
happen on particular locations (i.e. at specific nucleic acids) of the DNA cause MPN relevant
mutations. Inflammation increases the risk of mutations, including smoking, exposure to
ultraviolet light or certain chemicals [49,50,101–104]. It is this small probability which violates
a possible deterministic description with a simple mutation rate. Except for the mutation part,
the model will be deterministic and continuous. In most of our work, we studied the develop-
ment right after the first malignant mutation has occurred (denoted the first insult). In these
cases, the simulations start with one malignant stem cell. Meanwhile, the number of all other
cells are in a healthy steady state with the mutation rate put to zero. The approach is justified
by the fact that including a non-zero mutation rate did not affect the outcome of the model.
The equations are all of the general form,
Change in amount of a
compartment per time
( )
¼
rate of generation times
the generating source
( )
 
rate of elimination times the amount
in the compartment considered
( )
resulting in specific systems of ordinary differential equations as given in S1 Appendix.
Mathematical modeling in myeloproliferative cancer
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Whenever cells die the debris have to be engulfed by phagocytic cells, e.g. neutrophils and
macrophages while a hierarchic cascade of pro- and anti-inflammatory cytokines are released
[96–98,110]. Following the parsimonious principle, we let the dead cells (a) up-regulate the
amount of phagocytic cells (s) with rate constant rs per dead cell while they are eliminated with
a rate es. In addition, endotoxins, smoking and other environmental factors may add to the
inflammatory response; thus we add such a term (characterized by the lightning symbol in Fig
1). Since MPNs develop on time-scale years and inflammatory immune processes are fast (on
time-scale hours-days), we assume that the amount of phagocytic cells is balanced by the cyto-
kines levels in a fixed ratio. Thus, the cytokine level is proportional to the phagocytic level why
the inflammatory compartment (s) represents both (up to a possible proportionality constant
which may be incorporated into the rate constants). Meanwhile, the amount of dead cells is
down-regulated as a second order elimination process, -eaas, with rate constant ea. Dead cells
are produced by d0x0+dy0y0+dx1x1+dy1y1 per time denoted the turnover, which is assessed
by the plasma concentration of lactic dehydrogenase (LDH). It is well-known that the inflam-
matory level affects the mutation rate [104] and the self-renewal rates [105]. For simplicity, we
take these to be proportional with the inflammatory level (of course saturation may occur) but
since the level (a) settles at constant levels so does the inflammatory level (s), which may be
thought of as the amount of inflammatory cytokines which have been shown to be increased
in patients with MPNs and several in a step-wise manner from controls over the early cancer
stages (ET, PV) to the advanced cancer stage–myelofibrosis (PMF) (S1 Appendix) [40–46].
Thus, it turns out that various specific cytokines (IL-1β, IL-1RA, IL-2R, IL-6, IL-8, IL-10, IL-
12) and C-reactive protein (CRP)—a conventional biomarker of inflammation—are linearly
correlated with the inflammatory level (s). These cytokines have been chosen for validation of
our model since elevated levels of several of these cytokines have been associated with an infe-
rior survival [44]. Likewise, elevated levels of CRP have been shown to be associated with
shortened leukemia-free survival in patients with myelofibrosis [42]. Of note, the inflamma-
tory cytokine IL-8 have been reported to be of particular interest in the context of MPN patho-
genesis [57–60]. These extra pools of cells are depicted in Fig 1 along with the rates governing
the dynamics. This establishes the coupled inflammatory-MPN model. The full system of
mathematical equations, representing the model is described in Table B in S1 Appendix
including default parameter values.
Model calibration, validation, and results
The model is inspired by Dingli and Michor, and therefore the parameter values are based
upon their values [92]. However, we have adjusted them to obtain more appropriate saturation
levels in agreement with data (see Fig 2 and the reported values in Table C in S1 Appendix).
First, the model is calibrated to the situation of no MPN cancer cells (y0i = 0 and y1i = 0). In
this situation, we expect a stable steady state such that the number of HSC is approximately
104 and that of HMC is approximately 1010. These choices are compromises between reported
values for the number of HSC [78, 86, 88, 89, 92].
From the steady state condition we have the number of dead cells to be
ax ¼
dx0 x0þdx1 x1
eas
 103. We further expect rx>dx0 + ax and dx0dx1. When allowing for
MPN development the healthy state becomes unstable when perturbed by the malignant
stem cells. Thus, we expect ry >rx.
In the final stage the in silico patient will have vanishing hematopoietic cells and the MPN
cells will approach a stable steady state with a higher amount of MPN cells than normal
hematopoietic cells in the healthy steady state. This is accomplished by choosing all the c-
Mathematical modeling in myeloproliferative cancer
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values equal in order to keep the model as simple as possible and the number of parameters as
few as possible. Likewise, the parsimonious principle suggests dy0 = dx0, ay = ax and Ay = Ax.
The JAK2V617F allele burden has been reported to have median values of 7% (95% CL
2–15%; range 1–39%), 33% (95% CL 20–40%; range 1–92%) and 67% (95% CL 52–95%; range
37–99%) in ET, PV and PMF patients, respectively [19]. It follows that the model output per-
fectly resamples these dynamic changes in the JAK2V617F mutational load (Fig 3). Additional
details are given in the S1 Appendix section.
All these attempts in calibrating the model may simultaneously be considered as validation
since they performed successfully. However, the model may be validated further by predicting
affected cytokine levels from the inflammatory level. As indicators of the inflammatory level,
we refer to those cytokines, which are considered most important in the context of MPNs: IL-
1β, IL-1RA, IL-2R, IL-6, IL-8, IL-10, IL-12 and the inflammation biomarker CRP which all
turned out to be linearly correlated with the inflammatory level (s).
For the specific cytokines (Ci) tabulated in the S1 Appendix, we have ‘Normal’, ‘PV’, and
‘PMF’ median values (mij, where index i specifies the cytokine and index j refers to ‘Normal’,
‘PV’ and ‘PMF’ states) for each. Then we find ki1 and ki2 such that mij = ki1 sj+ki2 where sj is the
value of s at year tj. Similarly, LDH values were demonstrated to be correlated and compared
to the total rate of dying cells DI = dx0x0 + dx1x1 + dy0y0 + dy1y1. The results are summarized
Fig 2. Model calibration. A) Plateaus to the left show the amount of hematopoietic stem cells x0 (upper
plateau) and that for MPN stem cells y0 (lower plateau) whereas the plateaus to the right show the amount of
hematopoietic stem cells x0(lower plateau) and MPN mature cells y0 (upper plateau). B) Plateaus to the left
show the amount of hematopoietic mature cells x1 (upper plateau) and that for MPN mature cells y1 (lower
plateau) whereas the plateaus to the right show the amount of hematopoietic mature cells x1 (lower plateau)
and MPN mature cells y1 (upper plateau). The yellow and purple boxes show our data used for calibrating
(and validating) the model with further details in S1 Appendix. Yellow boxes show our “no MPN cancer
values”, and purple boxes show our “full blown” MPN values in the advanced myelofibrosis stage. Yellow
position marker shows the number of hematopoietic stem cells as used by Dingli & Michor [92], and black
position markers show the number of cells as used by Gentry et al. [86].
https://doi.org/10.1371/journal.pone.0183620.g002
Mathematical modeling in myeloproliferative cancer
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in Fig 4 which shows that the model predicts data very well. Only IL-6 seems to be less well
predicted.
Disallowing potential mutations and having no MPN-stem cells initially forces the model
system into a steady state where solutions are all constant after a possible initial transient
event. Introducing a mutation probability introduces a fatal malignant state; the higher the
mutation probability is the faster the malignant state develops. A typical scenario is shown in
Fig 3A along with a curve of the allele burden development (Fig 3B). The Figure depicts both
Fig 3. Left: Typical development in stem cells (top panel A) and mature cells (bottom panel B). Healthy
hematopoietic cells (full blue curves) dominate in the early phase where the number of malignant cells
(stipulated red curves) are few. The total number of cells is also shown (dotted green curves). When a stem
cell mutates without repairing mechanisms, a slowly increasing exponential growth starts. At a certain stage,
the malignant cells become dominant, and the healthy hematopoietic cells begin to show a visible decline.
Finally, the composition between the cell types results in a takeover by the malignant cells, leading to an
exponential decline in hematopoietic cells and ultimately their extinction. The development is driven by an
approximately exponential increase in the MPN stem cells, and the development is closely followed by the
mature MPN cells. Right: B)The corresponding allele burden (7%, 33% and 67% corresponding to ET, PV,
and PMF, respectively) defined as the ratio of MPN mature cells to the total number of mature cells.
https://doi.org/10.1371/journal.pone.0183620.g003
Fig 4. Model validation. Cytokines A) IL-1β, B) IL-1RA, C) IL-2R, D) IL-6, E) IL-8, F) IL-10, G) IL-12 and H)
C-reactive proteins (CRP) are approximatively linearly correlated with the inflammatory level s. For the
specific cytokines, we have from left to right ‘Normal’, ‘PV’, and ‘PMF’ median values (yellow columns) for
comparison based on the predicted inflammatory level s (full blue curve) as a function of time after the first
insult. I) Similarly, LDH is correlated with and compared to the total rate of dying cells DI = dx0x0 + dx1x1 +
dy0y0 + dy1y1.
https://doi.org/10.1371/journal.pone.0183620.g004
Mathematical modeling in myeloproliferative cancer
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modeling of the development of MPN from normal HSC and the early MPN diseases stages
(ET/PV) to the advanced myelofibrosis stage.
Having a continuous mutation rate, it will take 24 years for the disease to develop to an
allele burden of 7% (e.g. ET) and after additional four years the allele burden reaches 33% (e.g.
transformation of ET to PV) to become 67% (e.g. transformation of PV to post-PV myelofi-
brosis) at year 36 after the first stem cell mutation. Disallowing mutations in the model and
initially including a single malignant stem cell and no malignant mature cells shifts the allele
burden curve by one year to the left on the time axis.
Thus, the mutation of an HSC to MPN SC triggers the disease. Once an MPN stem cell is
established the disease can progress without further mutations.
The baseline inflammatory load (stimulus) is arbitrarily set to 7 pg/ml per day during nor-
mal circumstances. It is an exogenous stimulation of the immune system, which leads to an
inflammatory level of 3.61 pg/ml, increasing to 3.66 pg/ml in MPNs. This corresponds to a
baseline of 700 dead cells (in the hematopoietic steady state) before MPN develops remarkably.
A doubling of the baseline inflammatory level is directly affecting the inflammation load (cyto-
kine level) and thereby affecting the rest of the system as dictated by the model equations. In
Fig 5 is depicted that shortening the exposure time of inflammation load is associated with
deceleration of disease progression.
Discussion
Chronic inflammation is characterized by persistently activated immune cells, DNA damage,
tissue destruction, remodeling and fibrosis [106]. In patients with MPNs, these processes are
exemplified by the advanced myelofibrosis stage [4, 29], which accordingly might be consid-
ered to develop as the consequence of chronic inflammation in the bone marrow–“the
inflamed bone marrow” and “the wound that won’t heal” [4, 29,107,108]. Herein, we for the
first time use mathematical modelling to substantiate the concept that MPN progression is
facilitated by chronic inflammation and that ET and PV are linked through increasing
JAK2V617F allele burden [19] which is destined to happen as time increases without interfer-
ence. Importantly, we were able to create the inflammation-MPN model based upon current
knowledge on the interactions between inflammatory cytokines, hematopoietic stem cells and
progenitors, and the bone marrow microenvironment [31–33,35–37,105]. By mathematical
modelling of all these interactions, our integrated inflammation-MPN model was created. The
model was validated from current data on circulating inflammatory cytokines in MPNs
[40,44–46], thereby substantiating inflammation to be a highly potent stimulus for clonal evo-
lution and cancer progression in MPNs. In the context that elevated CRP levels have been
shown to be associated with shortened leukemia-free survival in myelofibrosis [42], it is of
interest that our model was excellently validated by data on CRP levels in the different MPN
disease stages as well.
Mathematical modelling has been used to describe the impact of chronic inflammation and
immune deregulation in aging [109] and several diseases, including type 1 diabetes mellitus
[110], rheumatoid arthritis [96] and colitis-associated colon cancer [111]. Based upon the
known association between respiratory infections and chronic inflammation, Herald described
a general model of inflammation [97]. In this model, a system of nonlinear ordinary differen-
tial equations was used to describe interactions between macrophages, inflammatory and anti-
inflammatory cytokines and bacteria. Though initiated by bacteria as the stimulus to trigger
chronic inflammation, their study focused on chronic inflammation in the absence of patho-
gens as well [97]. Of note, even small changes in parameters of importance for inflammatory
cytokine production and macrophage sensitivity to cytokines resulted in dramatically different
Mathematical modeling in myeloproliferative cancer
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model behaviors [97]. According to this model chronic inflammation is not triggered when
the immune system is functioning properly. However, in patients with a dysfunction of the
immune system positive feedback of the inflammatory cytokine network is prone to induce
chronic inflammation. Furthermore, if the macrophage population is more sensitive to inflam-
matory cytokines small perturbations initiated by the inflammation stimulus will also lead to
chronic inflammation [97]. In this context, it is intriguing to consider if the inherited genetic
predisposition to acquire the JAK2V617F-mutation due to the haplotype 46/1 [112–117],
which also confers an increased risk of (other) inflammatory diseases (e.g. Crohns’ disease)
[118,119] and /or acquired genetic instability due to sustained chronic inflammation (chronic
inflammatory diseases or toxin exposure (e.g. smoking) might further increase the risk of
developing MPN—a hypothesis originally proposed by Hermouet et al [33,35]. Importantly,
the hypersensitivity of clonal MPN-cells to exogenous and endogenous growth factors and
inflammatory cytokines might also more easily lead to a chronic inflammatory state–similar to
the increased sensitivity of the macrophage population leading to chronic inflammation in the
Fig 5. Investigation of increased inflammatory load at various onsets and durations. Blue curve is default
parameters corresponding to Fig 3, red dotted is a doubling of inflammatory load, full red curve is a doubling of
inflammatory load in year 0–20, then back to default level, black dotted curve is inflammatory doubling from year 10,
the full black is inflammatory doubling year 10–30. Upper: Increasing inflammatory load has a boosting effect on
MPN MC (A) as well as on HMC (B). Lower: Displaying the results in terms of the clinically available quantity, total
blood cell count, also shows a boosted effect with increasing inflammatory load (C). The allele burden of JAK2
mutated blood cells similarly shows that increased inflammation increases disease development (D). There is a clear
effect of MPN promotion with increasing inflammatory load, earlier onset, and exposure time. Lowering inflammatory
load makes disease progression less rapid. Maintaining a doubling (red dotted curve) shifts the allele burden curve to
the left by two years. Shortening the exposure time of inflammatory load weakens the disease progression. The
inflammation has a fast impact on the total number of blood cells, which typically changes by 25% within the first year
after doubling or reducing the inflammatory load by 50%.
https://doi.org/10.1371/journal.pone.0183620.g005
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Herald model and also implemented in the Hermouet model, implying an enhanced myelo-
monocytic response to cytokine stimulation [33,35].
In the Herald model and the model described by Nielsen et al in regard to type 1 diabetes
mellitus, the macrophages constituted an important compartment [97,110]. The monocyte-
macrophage cell lineage is of major importance in the context of inflammation and cancer
development. In our MPN-inflammation model bone marrow macrophages are also of utmost
importance—both in regard to release of inflammatory cytokines, but also in regard to the
development of myelofibrosis. Thus, in MPNs the monocyte-macrophage cell—together with
the megakaryocyte (MK) cell lineage—are considered to be responsible for the development of
myelofibrosis by the release of a number of growth factors and inflammatory cytokines that
stimulate fibroblast proliferation [36,120,121]. The “Herald Model” is in several aspects equiv-
alent to our model when considering substituting “bacteria”in the “Herald Model” by any nox-
ious inflammatory stimulus. In fact, we implement yet another cell lineage—the MKs—as the
source of a continuous release of products that stimulate the vicious inflammation circle,
implying ultimately the development of cancer—the MPNs. As previously outlined, our math-
ematical modelling of the concept of chronic inflammation in MPNs is also supported by the
elegant model described by Hermouet and co-workers [33,35], in which the JAK2 46/1 haplo-
type was proposed as a marker of inappropriate myelomonocytic response to cytokine stimula-
tion, leading to increased risk of inflammation, myeloid neoplasms, and impaired defense
against infection [33]. Indeed, the Hermouet model for chronic inflammation [33,35] fits
exceedingly well with the Herald model of general inflammation [97] and our mathematical
modelling of MPNs as “A Human Inflammation Mode for Cancer Development [29–32]. In
this regard, chronic inflammation and immune deregulation in MPNs might act as a trigger
for later development of AML and MDS in line with the known association of inflammatory
signaling and cancer [24–27]. The above models are additionally supported by the hypothetical
model by Takizawa et al. (2010) [122], describing how chronic inflammatory processes might
impinge on hematopoiesis, potentially fostering hematopoietic stem cell diseases, including
MPNs. By inducing high proliferation of most HSCs, chronic inflammation might give rise to
both exhaustion of the HSC pool and an even greater risk to accumulate genetic alterations in
HSCs. Furthermore, by inflammatory stimuli from the bone marrow microenvironment these
genetically altered HSCs might be rescued or “cancer cell niche” for later development of a
hematological cancer [122].
The perspectives of our study are several. In the context that myelomonocytic cells (granu-
locytes, macrophages, monocytes) and MKs are all deeply involved in cancer development and
progression [123,124], chronic inflammation is associated with premature atherosclerosis
(atherothrombosis) [21–23, 29,30], in which both platelets and monocytes are highly impor-
tant (monocytes a link between atherosclerosis and cancer [28]) and platelets are intimately
involved in the metastatic process in cancer [124]—and likely in MPNs as well [125]—the ave-
nue is opened for studying all these aspects by using mathematical modelling of current
knowledge of the impact of chronic inflammation and immune deregulation in patients with
MPNs. Ultimately, mathematical modelling may also be able to substantiate which agents to
be used in MPNs in order to induce “minimal residual disease”[125–129] and the importance
of early intervention with agents that directly target both the malignant clone (interferon-
alpha2) [126–129] and the inflammatory process (JAK1-2 inhibition with e.g. ruxolitinib)
[130].
In conclusion, we have for the first time applied mathematical modelling as a tool to
deliver the proof of concept that chronic inflammation is closely linked to the development of
the MPNs—myeloproliferative cancers which today are considered to be “chronic inflamma-
tory diseases”, in which chronic inflammation may be a driving force for clonal expansion and
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ultimately the development of AML [4, 29–32,39]. Studies are ongoing to elucidate the above
perspectives by mathematical modelling. In this regard, mathematical modelling of resolution
of inflammation may be highly important [98] and useful to support the decision-making
which agents to use in the future for patients with MPNs in order to induce minimal residual
disease and hopefully cure.
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